Market Matters Ep. 12: How HIMS Could Benefit From FDA Changes

<p>Raul Shah, CEO of DocShah Financial, analyzes the potential Wall Street implications of the FDA’s impending decision on peptide regulation, takes a closer look at how Hims &amp; Hers could benefit from approval and shares his health care sector insights. Raul also explains why he still believes in UnitedHealth and why he’ll always be a value investor.</p><p><br></p><p>======== Schwab Network ========</p><p>Empowering every investor and trader, every market day.</p><p> </p><p>Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe</p><p>Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185</p><p>Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7</p><p>Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch</p><p>Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore</p><p>Watch on DistroTV - https://www.distro.tv/live/schwab-network/</p><p>Follow us on X – https://twitter.com/schwabnetwork</p><p>Follow us on Facebook – https://www.facebook.com/schwabnetwork</p><p>Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/</p><p> </p><p>About Schwab Network - https://schwabnetwork.com/about</p>